stockportfolio.pro
Stocks / ETON vs PCRX
ETON vs PCRX
Eton Pharmaceuticals, Inc. and Pacira BioSciences, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Eton Pharmaceuticals, Inc. (ETON) | Pacira BioSciences, Inc. (PCRX) | |
|---|---|---|
| Market cap | $0.9B | $0.9B |
| Revenue (latest FY) | $79.95M | $726.41M |
| Net income (latest FY) | $-4.60M | $7.03M |
| Revenue growth (5y CAGR) | 359.6% | 11.1% |
| Net margin | -5.8% | 1.0% |
| Return on equity | -17.6% | 1.0% |
| P/E ratio | — | 180.3 |
| Dividend yield | — | — |
| Profitable years (of last 10) | 0 | 5 |
| Positive free cash flow | Yes | Yes |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open ETON — free Open PCRX — freeFrequently asked questions
Which is bigger, ETON or PCRX?
Pacira BioSciences, Inc. is larger by market capitalization — $0.9B versus $0.9B.
Which grows faster, ETON or PCRX?
Over the last five fiscal years, Eton Pharmaceuticals, Inc. grew revenue faster — 359.6%/yr versus 11.1%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.